197 related articles for article (PubMed ID: 15306259)
1. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
[TBL] [Abstract][Full Text] [Related]
2. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.
Reiner A; Lafferty DC; Wang HB; Del Mar N; Deng YP
Neurobiol Dis; 2012 Jul; 47(1):75-91. PubMed ID: 22472187
[TBL] [Abstract][Full Text] [Related]
3. Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.
Wang H; Del Mar N; Deng Y; Reiner A
Neurosci Lett; 2021 Oct; 763():136180. PubMed ID: 34416343
[TBL] [Abstract][Full Text] [Related]
4. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
[TBL] [Abstract][Full Text] [Related]
5. Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice.
Olive MF; Becker HC
Alcohol; 2008 May; 42(3):191-7. PubMed ID: 18420113
[TBL] [Abstract][Full Text] [Related]
6. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
[TBL] [Abstract][Full Text] [Related]
8. Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.
Stover JF; Sakowitz OW; Beyer TF; Dohse NK; Kroppenstedt SN; Thomale UW; Schaser KD; Unterberg AW
J Neurotrauma; 2003 Apr; 20(4):315-26. PubMed ID: 12866811
[TBL] [Abstract][Full Text] [Related]
9. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
Engel M; Snikeris P; Matosin N; Newell KA; Huang XF; Frank E
Psychopharmacology (Berl); 2016 Apr; 233(8):1349-59. PubMed ID: 26861891
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.
Lea PM; Movsesyan VA; Faden AI
Br J Pharmacol; 2005 Jun; 145(4):527-34. PubMed ID: 15821750
[TBL] [Abstract][Full Text] [Related]
11. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.
Woolley ML; Pemberton DJ; Bate S; Corti C; Jones DN
Psychopharmacology (Berl); 2008 Feb; 196(3):431-40. PubMed ID: 18057917
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of selective group II mGluR activation in brain trauma and traumatic neuronal injury.
Movsesyan VA; Faden AI
J Neurotrauma; 2006 Feb; 23(2):117-27. PubMed ID: 16503796
[TBL] [Abstract][Full Text] [Related]
13. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.
Chen HH; Stoker A; Markou A
Psychopharmacology (Berl); 2010 May; 209(4):343-50. PubMed ID: 20217053
[TBL] [Abstract][Full Text] [Related]
14. Early defect of transforming growth factor β1 formation in Huntington's disease.
Battaglia G; Cannella M; Riozzi B; Orobello S; Maat-Schieman ML; Aronica E; Busceti CL; Ciarmiello A; Alberti S; Amico E; Sassone J; Sipione S; Bruno V; Frati L; Nicoletti F; Squitieri F
J Cell Mol Med; 2011 Mar; 15(3):555-71. PubMed ID: 20082658
[TBL] [Abstract][Full Text] [Related]
15. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
[TBL] [Abstract][Full Text] [Related]
16. Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain.
Osikowicz M; Mika J; Makuch W; Przewlocka B
Pain; 2008 Sep; 139(1):117-126. PubMed ID: 18442882
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence.
Hao Y; Martin-Fardon R; Weiss F
Biol Psychiatry; 2010 Aug; 68(3):240-8. PubMed ID: 20416862
[TBL] [Abstract][Full Text] [Related]
18. BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.
Reiner A; Wang HB; Del Mar N; Sakata K; Yoo W; Deng YP
Brain Res; 2012 Sep; 1473():161-72. PubMed ID: 22820300
[TBL] [Abstract][Full Text] [Related]
19. Effects of metabotropic glutamate receptor ligands on male sexual behavior in rats.
Li X; Higley A; Song R; Xi ZX
Neuropharmacology; 2013 Mar; 66():373-81. PubMed ID: 22968089
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice.
Kozela E; Pilc A; Popik P
Psychopharmacology (Berl); 2003 Jan; 165(3):245-51. PubMed ID: 12442203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
